Norikazu Masuda - Concepedia

Author

Norikazu Masuda

Also Known As

Daigo Yamamoto, Hiroji Iwata, Masuda N, Masuda, Norikazu, N Masuda, N. Masuda, Norihito Masuda, Norikazu MASUDA, Norikazu Masuda, Valeria Masiello

693

Publications

29.3K

Citations

H-Index

102

Concepts

All Affiliations

Osaka National Hospital Aichi Cancer Center Shikoku Cancer Center Saitama Cancer Center Kyoto University

About

Norikazu Masuda is an author at Osaka National Hospital specializing in breast cancer, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	123	13.3K
2	Health Sciences	20	33	7.7K
3	Nursing	2	2	58
4	Biostatistics	2	2	36
5	Engineering	1	1	105

Norikazu Masuda

234

Publications

28.4K

Citations

H-Index

Page 1

	Year	Citations
Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, New England Journal of Medicine	2017	3.1K
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, New England Journal of Medicine	2017	1.8K
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, The Lancet Oncology Breast OncologyHealth SciencesMedicinePharmacologyClinical Trials	2016	1.8K
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Javier Cortés, David W. Cescon, Hope S. Rugo, The Lancet Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast Cancer	2020	1.7K
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy George W. Sledge, Masakazu Toi, Patrick Neven, Journal of Clinical Oncology Breast OncologyCancer ManagementGynecologyPharmacotherapyPurpose Monarch 2	2017	1.6K
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, New England Journal of Medicine	2018	1.2K
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Javier Cortés, Hope S. Rugo, David W. Cescon, New England Journal of Medicine	2022	968
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 George W. Sledge, Masakazu Toi, Patrick Neven, JAMA Oncology	2019	941
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Sandra M. Swain, David Miles, Sung‐Bae Kim, The Lancet Oncology End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology	2020	854
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria Hiroshi Katayama, Yukinori Kurokawa, Kenichi Nakamura, Surgery Today	2015	757

Page 1